Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

6 Jan 2021

Abstract excerpt

PURPOSE Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value of minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within the Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style consolidation (araC, daunorubicin, etoposide/mitoxantrone, araC,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Childhood Cancer Survivors' Quality of Life
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33405950
DOI: 10.1200/jco.20.02333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolPMID 33405950Read ↗

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolSemantic proximity Read ↗

Updates in the biology and therapy for infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Multiple Lineage Switches in KMT2A Rearranged Infant Leukemia, Responsive to Combination Therapy with CPX-351 and InotuzumabSemantic proximity Read ↗

Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study.Semantic proximity Read ↗

Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapySemantic proximity Read ↗

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceSemantic proximity Read ↗

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocolSemantic proximity Read ↗

How I treat ETP-ALL in childrenSemantic proximity Read ↗

Crossing Our T’s: An Unusual Presentation of Infantile T-cell LeukemiaSemantic proximity Read ↗

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center settingSemantic proximity Read ↗

Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.Semantic proximity Read ↗

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.